[go: up one dir, main page]

DE602006011607D1 - In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie - Google Patents

In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie

Info

Publication number
DE602006011607D1
DE602006011607D1 DE200660011607 DE602006011607T DE602006011607D1 DE 602006011607 D1 DE602006011607 D1 DE 602006011607D1 DE 200660011607 DE200660011607 DE 200660011607 DE 602006011607 T DE602006011607 T DE 602006011607T DE 602006011607 D1 DE602006011607 D1 DE 602006011607D1
Authority
DE
Germany
Prior art keywords
cancer
individual
vitro method
identifying
cancer therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE200660011607
Other languages
English (en)
Inventor
Sanjuan Juan Carlos Lacal
De Molina Ana Ramirez
Ortega David Gallego
Coronel Monica Banez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Consejo Superior de Investigaciones Cientificas CSIC
Original Assignee
Consejo Superior de Investigaciones Cientificas CSIC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior de Investigaciones Cientificas CSIC filed Critical Consejo Superior de Investigaciones Cientificas CSIC
Publication of DE602006011607D1 publication Critical patent/DE602006011607D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G01N33/57515—
    • G01N33/5752—
    • G01N33/57595—
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE200660011607 2005-04-13 2006-04-12 In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie Active DE602006011607D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200500875 2005-04-13
PCT/ES2006/070047 WO2006108905A1 (es) 2005-04-13 2006-04-12 Método in vitro para identificar compuestos para terapia del cáncer

Publications (1)

Publication Number Publication Date
DE602006011607D1 true DE602006011607D1 (de) 2010-02-25

Family

ID=37087793

Family Applications (1)

Application Number Title Priority Date Filing Date
DE200660011607 Active DE602006011607D1 (de) 2005-04-13 2006-04-12 In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie

Country Status (16)

Country Link
US (3) US8481256B2 (de)
EP (2) EP1889920B1 (de)
JP (1) JP4759612B2 (de)
KR (3) KR101352142B1 (de)
CN (3) CN103215351A (de)
AT (1) ATE454465T1 (de)
BR (1) BRPI0607507A2 (de)
CA (1) CA2604803A1 (de)
DE (1) DE602006011607D1 (de)
DK (1) DK1889920T3 (de)
ES (1) ES2341729T3 (de)
MX (1) MX2007012668A (de)
PL (1) PL1889920T3 (de)
PT (1) PT1889920E (de)
RU (1) RU2434946C2 (de)
WO (1) WO2006108905A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007138143A2 (es) 2006-05-29 2007-12-06 Consejo Superior De Investigaciones Cientificas Anticuerpos monoclonales anti-colina quinasa alfa y su uso en técnicas analíticas, de diagnóstico del cáncer y en la preparación de medicamentos
CA2721071C (en) 2008-04-11 2017-10-17 Cytotech Labs, Llc Methods and use of inducing apoptosis in cancer cells
MX2011000147A (es) * 2008-07-04 2011-05-24 Traslational Cancer Drugs Pharma S L Metodos para el tratamiento y diagnostico del cancer.
US20100068302A1 (en) * 2008-09-17 2010-03-18 Traslational Cancer Drugs Pharma, S.L. Methods and compositions for the treatment of cancer
BR112013032857A2 (pt) * 2011-06-20 2017-01-24 Traslational Cancer Drugs Pharma S L método para prever a resposta clínica à quimioterapia em um indivíduo com câncer
JP2013230145A (ja) * 2012-04-30 2013-11-14 Masahiko Sato 細胞集団の状態を評価するための方法、候補化合物の発癌性を評価するための方法、潜在的な抗癌化合物の抗癌活性を評価するための方法及び治療用細胞集団の品質を評価するための方法
CA3213528A1 (en) 2012-05-15 2013-11-21 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
WO2015028662A1 (en) * 2013-08-30 2015-03-05 Consejo Superior De Investigaciones Cientificas (Csic) Compositions and methods for characterization and amelioration of rheumatoid arthritis
RU2552305C1 (ru) * 2014-04-04 2015-06-10 Федеральное государственное бюджетное учреждение науки Институт физиологии природных адаптаций Уральского отделения Российской академии наук Способ прогнозирования риска развития злокачественных новообразований
WO2017059551A1 (en) 2015-10-08 2017-04-13 Zymeworks Inc. Antigen-binding polypeptide constructs comprising kappa and lambda light chains and uses thereof
RU2657417C1 (ru) * 2017-05-29 2018-06-13 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ прогнозирования риска озлокачествления узловых образований у больных с эндокринологическими заболеваниями
RU2713795C1 (ru) * 2019-06-13 2020-02-07 Федеральное государственное бюджетное образовательное учреждение высшего образования "Самарский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ прогнозирования возможности озлокачествления опухоли яичника у женщин репродуктивного возраста
CN117849343A (zh) * 2021-05-31 2024-04-09 浙江大学 基于CHKα的非代谢功能作为癌症治疗、诊断和预后预测之靶标的应用
WO2025196502A1 (en) 2024-03-20 2025-09-25 North Carolina Agricultural & Technical State University Choline kinase inhibitors as a therapeutic treatment for obesity

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
JPH05243020A (ja) * 1992-03-02 1993-09-21 Rohm Co Ltd チップネットワーク型抵抗器
JP3399948B2 (ja) * 1992-06-26 2003-04-28 ザ トラスティーズ オブ プリンストン ユニバーシティ Ｐ９０抗体またはプローブを用いた前癌細胞または癌細胞の検出方法
WO1997006256A2 (en) 1995-08-09 1997-02-20 Institut National De La Sante Et De La Recherche Medicale Isolated nucleic acid molecules useful as leukemia markers and in breast cancer prognosis
JP3756612B2 (ja) * 1997-03-18 2006-03-15 ローム株式会社 チップ型抵抗器の構造及びその製造方法
KR100333298B1 (ko) * 1997-07-03 2002-04-25 모리시타 요이찌 저항기 및 그 제조방법
US20030077568A1 (en) * 2000-09-15 2003-04-24 Gish Kurt C. Methods of diagnosis of colorectal cancer, compositions and methods of screening for colorectal cancer modulators
JP4078042B2 (ja) * 2001-06-12 2008-04-23 ローム株式会社 複数の素子を有するチップ型電子部品の製造方法
JP3846312B2 (ja) * 2002-01-15 2006-11-15 松下電器産業株式会社 多連チップ抵抗器の製造方法
US20030186241A1 (en) 2002-03-20 2003-10-02 Ken-Shwo Dai Human choline/ethanolamine kinase (HCEK)-related gene variant associated with lung cancers
US20040115656A1 (en) * 2002-12-16 2004-06-17 Tai-Jay Chang Treating breast cancer
RU2246248C1 (ru) * 2003-06-16 2005-02-20 Ростовский научно-исследовательский онкологический институт МЗ РФ Способ прогнозирования развития метахронного рака молочной железы
WO2005001089A1 (ja) * 2003-06-27 2005-01-06 Seikagaku Corporation 癌の検出方法
JP2005073548A (ja) * 2003-08-29 2005-03-24 National Cancer Center-Japan 卵巣明細胞腺癌の検査、治療、および治療薬のスクリーニングのための、ＨＮＦ−１βの利用
ES2277568B1 (es) 2005-12-30 2008-04-01 Consejo Superior De Investigaciones Cientificas Derivados de triterpenoquinona y triterpenofenoles y su aplicacion para el tratamiento de tumores y enfermedades parasitarias.

Also Published As

Publication number Publication date
CN103215351A (zh) 2013-07-24
CN102228689A (zh) 2011-11-02
US8481256B2 (en) 2013-07-09
US20110269948A1 (en) 2011-11-03
US20140023657A1 (en) 2014-01-23
MX2007012668A (es) 2008-03-11
PL1889920T3 (pl) 2010-06-30
EP2246441B1 (de) 2015-12-16
DK1889920T3 (da) 2010-05-10
JP2008535511A (ja) 2008-09-04
KR20130086060A (ko) 2013-07-30
ATE454465T1 (de) 2010-01-15
KR20080080430A (ko) 2008-09-04
BRPI0607507A2 (pt) 2009-09-08
EP1889920B1 (de) 2010-01-06
CN101405403B (zh) 2013-07-10
CA2604803A1 (en) 2006-10-19
ES2341729T3 (es) 2010-06-25
EP1889920A1 (de) 2008-02-20
RU2434946C2 (ru) 2011-11-27
PT1889920E (pt) 2010-04-14
EP2246441A1 (de) 2010-11-03
KR101322705B1 (ko) 2013-10-29
CN101405403A (zh) 2009-04-08
US20090304575A1 (en) 2009-12-10
JP4759612B2 (ja) 2011-08-31
RU2007141930A (ru) 2009-05-20
WO2006108905A1 (es) 2006-10-19
KR101352142B1 (ko) 2014-02-17
US8901096B2 (en) 2014-12-02
KR20130006703A (ko) 2013-01-17

Similar Documents

Publication Publication Date Title
CY1111714T1 (el) Δεσμευτικες πρωτεϊνες αυξητικου παραγοντα ηπατοκυτταρων (hgf).
WO2020093006A8 (en) Methods of treating cancer in biomarker-identified patients with non-covalent inhibitors of cyclin-dependent kinase 7 (cdk7)
CY1122973T1 (el) Συνθεση υγρου διαπιδυσης η οποια περιλαμβανει ουσιες αναστολης της κρυσταλλωσης
ECSP088440A (es) Imidazopirazinas como inhibidores de proteinquinasa
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
EA200600078A1 (ru) Способы и композиции для лечения амилоидных заболеваний
ATE454465T1 (de) In-vitro-verfahren zur identifizierung von verbindungen zur krebstherapie
EA201690111A1 (ru) Имидазопиразиновые ингибиторы тирозинкиназы syk
DE602005019064D1 (de) Verfahren zur herstellung gefriergetrockneter blutplättchen, gefriergetrocknete blutplättchen enthaltende zusammensetzungen und verwendungsverfahren
BRPI0920261A8 (pt) Composto, composição farmacêutica, uso do composto, e, método para inibir ou modular atividade de proteína quinase em uma amostra biológica
EA201190043A1 (ru) Имидазопиразиновые ингибиторы syk
ECSP088350A (es) Pirazolopirimidinas como inhibidores de protein quinasas
CY1111437T1 (el) Τετραϋδροπυρρολοπυριμιδινοδιονες και η χρηση τους ως αναστολεων της ανθρωπινης ουδετεροφιλης ελαστασης
EP2061907A4 (de) Tcl1-expression in durch mir-29 und mir-181 regulierter chronischer lymphozyten-leukämie (cll)
CY1110162T1 (el) Φαρμακοτεχνικη μορφη και μεθοδοι για την αγωγη της θρομβοκυτταραιμιας
ATE497763T1 (de) Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen
CY1117174T1 (el) ΧΡΗΣΗ 24-norUDCA ΓΙΑ ΤΗΝ ΑΓΩΓΗ ΧΟΛΟΣΤΑΤΙΚΩΝ ΝΟΣΗΜΑΤΩΝ ΤΟΥ ΗΠΑΤΟΣ
BRPI0507645A (pt) anticorpo, método de detectar um distúrbio ósseo metabólico, kit para detectar um distúrbio ósseo metabólico, composição farmacêutica para o tratamento de um distúrbio ósseo metabólico, e, método de triar uma substáncia efetiva para tratar e/ou prevenir um distúrbio ósseo metabólico
DE602005012481D1 (de) 2,7-substituierte 5-amino-4-hydroxy-8-(1h-indol-5-yl)-octanamid derivate als renin inhibitoren zur behandlung von bluthochdruck
EA201071422A1 (ru) Способы лечения заболеваний, связанных с мейотическим кинезином
CY1114811T1 (el) Νεα κλασματα πρωτεϊνων γαλακτος και η χρηση τους για την προληψη ή τη θεραπεια των χρονιων φλεγμονωδων νοσων
ATE376419T1 (de) Carbostyril-derivate mit selektiven serotonin- aufnahme inhibitoren, zur behandlung von gemütskrankheiten
CY1116166T1 (el) Νεα μεθοδος για την αντιμετωπιση λοιμωξεων απο η.pylori
ATE489380T1 (de) Hydratformen von amg706
DE602005020113D1 (de) Verfahren zur behandlung von akuten rhinosinusitis

Legal Events

Date Code Title Description
8364 No opposition during term of opposition